173 related articles for article (PubMed ID: 11988811)
1. Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure.
Watts P; Hawksworth N
Eye (Lond); 2002 Mar; 16(2):132-5. PubMed ID: 11988811
[TBL] [Abstract][Full Text] [Related]
2. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
3. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
4. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension.
Gandolfi SA; Lim J; Sanseau AC; Parra Restrepo JC; Hamacher T
Adv Ther; 2014 Dec; 31(12):1213-27. PubMed ID: 25430900
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
7. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
8. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Natt NK; Gupta A; Singh G; Singh T
Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
[TBL] [Abstract][Full Text] [Related]
9. Intraocular pressure-lowering effects and safety of brimonidine/brinzolamide fixed combination after switching from other medications.
Inoue K; Kunimatsu-Sanuki S; Ishida K; Tomita G
Jpn J Ophthalmol; 2022 Sep; 66(5):440-446. PubMed ID: 35842568
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Chi W; Li A; Wang S; Zhu X
Eye Sci; 2013 Dec; 28(4):190-4. PubMed ID: 24961091
[TBL] [Abstract][Full Text] [Related]
11. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
15. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
16. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial.
Gandolfi SA; Cimino L; Mora P
Eur J Ophthalmol; 2003; 13(7):611-5. PubMed ID: 14552594
[TBL] [Abstract][Full Text] [Related]
17. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
18. Brimonidine allergy presenting as vernal-like keratoconjunctivitis.
Shah AA; Modi Y; Thomas B; Wellik SR; Galor A
J Glaucoma; 2015 Jan; 24(1):89-91. PubMed ID: 23632412
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
20. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]